Advertisement
Advertisement
IOVA
Iovance Biotherapeutics, Inc. Common Stock
3.92
USDSponsored
+0.30
+8.18%
Mar 25, 10:21 UTC -4
Open
IOVA Earnings Reports
Positive Surprise Ratio
IOVA beat 20 of 41 last estimates.
49%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$85.76M
/-$0.14
Implied change from Q4 25 (Revenue/ EPS)
-1.16%
/-22.22%
Implied change from Q1 25 (Revenue/ EPS)
+73.88%
/-61.11%
Iovance Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Feb 24, 2026, IOVA reported earnings of -0.18 USD per share (EPS) for Q4 25, missing the estimate of -0.17 USD, resulting in a -2.80% surprise. Revenue reached 86.77 million, compared to an expected 82.32 million, with a 5.40% difference. The market reacted with a +30.80% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.14 USD, with revenue projected to reach 85.76 million USD, implying an decrease of -22.22% EPS, and decrease of -1.16% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Arbutus Biopharma Corporation Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.03
Actual
-$0.02
Surprise
+43.98%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Sutro Biopharma, Inc.
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$4.43
Actual
-$5.29
Surprise
-19.39%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Xilio Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.69
Actual
$0.81
Surprise
+147.74%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
FAQ
What were Iovance Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Iovance Biotherapeutics, Inc. Common Stock reported EPS of -$0.18, missing estimates by -2.8%, and revenue of $86.77M, 5.4% above expectations.
How did the market react to Iovance Biotherapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 30.8%, changed from $2.89 before the earnings release to $3.78 the day after.
When is Iovance Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Iovance Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Iovance Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of $85.76M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement